2月27日，医渡科技(02158)再度实施股份回购，当日以每股约5.99港元的价格回购32.2万股，总耗资近 200万港元。截至目前，公司年内已完成19次回购，累计斥资已超7600万港元，以连贯动作彰显对自身 长期价值与AI医疗行业前景的坚定信心。 业务层面，医渡科技创新成果密集落地：旗下面向医生的临床循证智能体"医渡智循"正开展内测，由公 司提供核心技术支撑的海南自贸港传染病监测预警项目入选《2025年"数据要素×"大赛全国总决赛获奖 项目案例集》，获国家级认可。 近期，中航证券发布研报指出：国内外医疗公司持续布局AI产品与服务，包括医学影像、临床辅助决 策、精准医疗、健康管理、医疗信息化、药物研发以及医疗机器人等，通过降本增效、改善患者体验、 降低患病风险等方式全面赋能医药、医疗各个环节。AI正从"技术辅助"角色，升级为医疗产业"价值重 塑"和"效率革命"的核心驱动力，其商业价值正在从研发端向临床端、支付端和患者端全面渗透。 在投资主线的梳理中，中航证券明确将医渡科技列入"技术/数据平台型企业"类别，与讯飞医疗等同被 列为建议关注标的。 ...

证券之星消息，2月27日AI医疗板块较上一交易日上涨1.14%，爱迪特领涨。当日上证指数报收于 4162.88，上涨0.39%。深证成指报收于14495.09，下跌0.06%。AI医疗板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日AI医疗板块主力资金净流入22.14亿元，游资资金净流出14.73亿元，散户资金 净流出7.41亿元。AI医疗板块个股资金流向见下表： ...

从资金流向上来看，当日AI医疗板块主力资金净流出10.41亿元，游资资金净流入4.69亿元，散户资金 净流入5.73亿元。AI医疗板块个股资金流向见下表： 证券之星消息，2月26日AI医疗板块较上一交易日下跌0.24%，热景生物领跌。当日上证指数报收于 4146.63，下跌0.01%。深证成指报收于14503.79，上涨0.19%。AI医疗板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1: Google - Google has gained significant attention in the market due to its TPU chips and Gemini AI model, showcasing a competitive edge in AI technology [1] - In the past year, Google has outperformed its peers with a 70% increase in stock price, while Nvidia saw a 47% increase, and other tech giants like Microsoft and Amazon experienced slight declines [2] - As of Q4 2025, over 5,000 institutions held Google stocks, with a notable increase of over 30% in holdings, making it the most significantly increased position among tech giants [4] - Prominent investment firms have increased their holdings in Google, with Baillie Gifford raising its position in Google-C by over 29% and ARK Invest increasing its stake by over 60% [5][6] Group 2: Pinduoduo - Pinduoduo's stock has dropped over 20% since its peak in November 2022, underperforming compared to competitors like Alibaba and JD.com [7] - Despite the decline, analysts view this as a potential buying opportunity, citing Pinduoduo's valuation discount and strong user value proposition [9] - In Q4 2025, several major Chinese investment firms, including H&H and Hillhouse, have increased their positions in Pinduoduo, indicating strong consensus among investors [9] Group 3: Tempus AI - Tempus AI has emerged as a key player in the AI healthcare sector, focusing on diagnostic and data-driven solutions, and has a market capitalization exceeding $10 billion [12] - The company reported over $900 million in revenue for the first three quarters of 2025, reflecting an 84% year-over-year growth, despite a net loss of $190 million [12] - In Q4 2025, ARK Invest and other institutions have increased their stakes in Tempus AI, with ARK becoming its fourth-largest shareholder [12][14]

另据可靠消息，医渡科技临床循证智能体"医渡智循"已开启内测。据了解，该产品专为临床医生与医学 研究者打造，聚焦临床诊疗和科研场景的真实需求，本次内测邀请具备真实执业背景的一线医生参与， 通过真实执业场景的反馈进一步优化产品临床实用性。此前其打造的"医生Copilot"在单院实现日均被调 用近千次，覆盖了约70%的临床医护人员，成为医生诊疗全程的得力伙伴，"医渡智循"的推出进一步丰 富了其智能体产品矩阵。 当前AI医疗行业政策与技术双轮驱动，国家八部门联合印发的《"人工智能+医疗卫生"应用发展实施意 见》中明确2030年实现二级以上医院智能辅助诊断全覆盖，临床循证类工具成为行业刚需。医渡科技一 边以持续回购传递价值认可，一边加速产品创新落地，其在AI医疗赛道的竞争力持续夯实，长期发展 值得期待。 智通财经APP获悉，2月24日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.96港元的 价格回购72万股，总耗资近430万港元，延续2026年以来的密集回购节奏。自1月26日以来，公司已完成 17次回购，累计斥资超7200万港元，以持续的资本动作彰显对自身发展及行业前景的双重信心。 ...

Core Viewpoint - The company, Yidu Tech (02158), demonstrates confidence in its development and industry prospects through continuous share buybacks and product innovation in the AI healthcare sector [1]. Group 1: Share Buyback Activity - On February 24, Yidu Tech announced a share buyback of 720,000 shares at approximately HKD 5.96 per share, totaling nearly HKD 4.3 million [1]. - Since January 26, the company has completed 17 buybacks, with a cumulative expenditure exceeding HKD 72 million, reflecting a strong commitment to shareholder value [1]. Group 2: Product Development - Yidu Tech's clinical evidence-based AI tool, "Yidu Zhixun," has entered internal testing, aimed at clinical doctors and medical researchers, focusing on real-world clinical and research needs [1]. - The internal testing involves frontline doctors with real practice backgrounds to optimize the product's clinical usability based on actual feedback [1]. - The previously developed "Doctor Copilot" tool has been utilized nearly 1,000 times daily in a single hospital, covering about 70% of clinical healthcare personnel, indicating strong product adoption [1]. Group 3: Industry Context - The AI healthcare industry is driven by both policy and technology, with a joint issuance from eight national departments outlining plans for full coverage of intelligent diagnostic assistance in secondary hospitals by 2030 [1]. - Clinical evidence-based tools are becoming essential in the industry, positioning Yidu Tech favorably as it continues to innovate and reinforce its competitive edge in the AI healthcare sector [1].

证券之星消息，2月24日AI医疗板块较上一交易日下跌0.05%，浙数文化领跌。当日上证指数报收于 4117.41，上涨0.87%。深证成指报收于14291.57，上涨1.36%。AI医疗板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日AI医疗板块主力资金净流出16.62亿元，游资资金净流入2.42亿元，散户资金 净流入14.21亿元。AI医疗板块个股资金流向见下表： ...

Group 1 - The core viewpoint of the article highlights that Yidu Technology (02158) has demonstrated confidence in its intrinsic value through a series of share buybacks, totaling nearly 68 million HKD since the start of 2026's first buyback on January 26, completing 16 buybacks in less than a month [1][1][1] - The company repurchased 163,000 shares at approximately 6 HKD per share on February 20, costing over 970,000 HKD, marking its first buyback operation after the Spring Festival [1][1][1] Group 2 - The AI healthcare industry is currently experiencing a golden period of development, driven by both policy and market forces, with a comprehensive acceleration in commercialization [1][1][1] - The Chinese government has issued implementation opinions for the application development of "Artificial Intelligence + Healthcare," aiming to establish a number of clinical vertical large models by 2027 and achieve intelligent auxiliary diagnosis coverage in secondary hospitals by 2030 [1][1][1] - The market for AI healthcare in China is projected to grow from 8.8 billion CNY in 2023 to 315.7 billion CNY by 2033, with a compound annual growth rate of 43.1% according to Frost & Sullivan [1][1][1]

Core Viewpoint - The Hong Kong stock market has seen a continuous share buyback trend since 2026, with leading companies like Yidu Tech (02158) actively participating to demonstrate confidence in their intrinsic value and future development [1] Group 1: Share Buyback Activity - Yidu Tech announced a share buyback on February 16, repurchasing 404,000 shares at approximately HKD 5.91 per share, totaling nearly HKD 2.4 million [1] - This marks the 15th buyback since the beginning of 2026, with a cumulative expenditure of nearly HKD 67 million [1] - The buyback activity has been characterized by high frequency and steady intensity, with 15 buybacks completed in less than a month since the first buyback on January 26 [1] Group 2: Business Developments - Yidu Tech's recent collaboration with Huazhong University of Science and Technology's Tongji Hospital on a multimodal AI database project for gastrointestinal tumors has been selected for the Ministry of Industry and Information Technology's 2025 AI medical device innovation initiative [1] - The company's growth prospects have been recognized by institutions, with Citigroup maintaining a "Buy" rating and raising the target price to HKD 11 in February [1]

Group 1 - The core viewpoint of the article highlights the ongoing share buyback trend in the Hong Kong stock market since 2026, with leading companies like Yidu Tech (02158) actively participating to demonstrate confidence in their intrinsic value and future development [1] Group 2 - On February 16, Yidu Tech announced a share buyback of 404,000 shares at approximately HKD 5.91 per share, costing nearly HKD 2.4 million, marking its 15th buyback since 2026 and totaling close to HKD 67 million in expenditures [1] - The buyback activity of Yidu Tech is characterized by "high frequency and steady strength," having completed 15 buybacks in less than a month since the first buyback on January 26 [1] - Yidu Tech's business prospects have been positively impacted by recent developments, including the successful selection of a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Huazhong University of Science and Technology [1] - Citigroup maintained a "buy" rating for Yidu Tech in February and raised its target price to HKD 11, reflecting institutional recognition of the company's growth potential [1]